Clinical trials
Fibrosis clinical trials
Below are recruiting fibrosis clinical trials, each written for real people, not researchers. We’re tracking 414 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07707245Recruiting
Finding biomarkers in lung disease and lung cancer
This trial studies blood and tissue samples from people with COPD, IPF, or lung cancer to find markers that can help diagnose and predict these conditions. It aims to discover why some lung diseases progress to cancer.
Milan, MilanAges 18 years+ - NCT07683728Recruiting
Observational study of progressive pulmonary fibrosis (PPF) in China
This study is a registry that collects information from people in China who have progressive pulmonary fibrosis (PPF), a lung condition that gets worse over time. It aims to better understand the disease and help doctors improve care.
BeijingAges Any age - NCT07687459RecruitingPhase 3
Oral treatment for idiopathic pulmonary fibrosis
This trial tests an experimental pill called rentosertib for people with idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring. The study aims to see if the drug can slow down the disease and improve breathing.
Hefei, AnhuiAges 40 years+ - NCT06660992RecruitingPhase 3
Study of HSK31858 for non-CF bronchiectasis
This trial tests a new medicine, HSK31858, for people with non-cystic fibrosis bronchiectasis (a lung condition causing chronic cough and infections). It aims to see if the drug reduces lung flare-ups and improves symptoms.
Guangzhou, GuangdongAges 18 years+ - NCT07671911RecruitingPhase 3
Cough relief for pulmonary fibrosis
This trial tests a new extended-release medicine, nalbuphine, to reduce chronic coughing in people with idiopathic pulmonary fibrosis (a lung disease that scars the lungs). It may help make cough less frequent and less bothersome.
Newport Beach, CaliforniaAges 40 years+ - NCT05099939Recruiting
Monitoring sugar changes in adults with cystic fibrosis
This study uses continuous glucose monitoring (a sensor that checks blood sugar trends) to understand how sugar handling changes over time in people with cystic fibrosis. It may help doctors spot early “pre-diabetes” or abnormal sugar patterns sooner.
Montreal, QuebecAges 18 years+ - NCT07658755Recruiting
LiverSeek: Finding advanced liver scarring in MASLD
This study uses routine blood tests to find people with advanced liver scarring caused by a condition called MASLD. If you are between 50 and 75, have certain metabolic risks, and get blood work from your primary care doctor at select centers, you may be eligible.
Madrid, MadridAges 50–75 - NCT06125327RecruitingPhase 2/Phase 3
SC1011 for idiopathic pulmonary fibrosis (IPF)
This trial tests a new medication called SC1011 taken twice a day, compared to a placebo, to see if it can help people with IPF. It is for patients who were diagnosed within the last 5 years and have moderate lung function.
Beijing, Beijing MunicipalityAges 40–80 - NCT07629986Recruiting
How antibiotics work in cystic fibrosis patients on ETI therapy
This study measures how antibiotics are processed by the body in people with cystic fibrosis who are taking a combination drug called elexacaftor/tezacaftor/ivacaftor (ETI). Understanding this helps doctors prescribe the right antibiotic doses for patients on this newer treatment.
RoscoffAges 12 years+ - NCT05121779RecruitingPhase 1
PET-CT scan compares two tests for lung scarring
This early (Phase 1) study compares two types of PET-CT scans to see how well they detect and measure lung scarring (pulmonary fibrosis). It may help doctors choose the best scan test for diagnosis in the future.
Beijing, Beijing MunicipalityAges 18–80 - NCT06526923RecruitingPhase 1/Phase 2
Testing SP-101 gene therapy for cystic fibrosis
This trial tests a new gene therapy called SP-101 for cystic fibrosis. It aims to see if SP-101 is safe and effective for improving lung function.
Kansas City, KansasAges 18–65 - NCT07613827Enrolling by invitation
AI screening for fatty liver disease using CT scans
This study uses artificial intelligence to help doctors identify fatty liver disease from CT scans you may already be having. If eligible, you'll have some blood tests and possibly an ultrasound or MRI to confirm liver health, helping catch liver disease early.
Shenyang, LiaoningAges 18 years+ - NCT07616375RecruitingPhase 3
Safety Study of HSK31858 for Bronchiectasis
This study tests how safe an experimental inhaled medicine (HSK31858) is for people with non-cystic fibrosis bronchiectasis, a lung condition where airways are damaged and collect mucus. You can only join if you already completed a previous HSK31858 study.
Yixingcun, JiangxiAges 18 years+ - NCT07610837RecruitingPhase 2
Testing AZD2389 for fatty liver disease with scarring
This study tests whether a new drug called AZD2389 is safe and well-tolerated in adults with steatotic liver disease (fatty liver) that has progressed to advanced scarring. The trial aims to see if this drug might help slow or improve liver damage in people with this condition.
Chandler, ArizonaAges 18 years+ - NCT04971577RecruitingPhase 2/Phase 3
Simvastatin for alcohol-related liver scarring in stable adults
This trial studies whether simvastatin (a cholesterol medicine) can improve or slow scarring of the liver caused by long-term alcohol use. Participants must have confirmed liver fibrosis on biopsy and be in a stable (compensated) phase of liver disease.
BarcelonaAges 18 years+ - NCT07588854Recruiting
Liver Stiffness Testing and Biopsy for Chronic Liver Disease
This study compares two non-invasive ultrasound methods (EUS-SWQ and FibroScan) with liver biopsy to see how well they detect liver scarring in patients with chronic liver disease. The goal is to improve how doctors diagnose and monitor liver damage from conditions like hepatitis B and fatty liver disease.
ShanghaiAges 18–80 - NCT07569419RecruitingEarly Phase 1
Testing Linaclotide for Cystic Fibrosis Bowel Function
This early-stage study tests whether a medication called linaclotide can help improve bowel function in people with cystic fibrosis. Researchers will use MRI scans and other tests to see how the medication affects your digestive system.
NottinghamAges 18–65 - NCT07572383RecruitingPhase 2
Imaging Study of Immunosuppression for Progressive Lung Fibrosis
This study uses advanced imaging to see how immunosuppressive medications (like mycophenolate or prednisone) affect lung scarring in patients with certain types of lung fibrosis. You would have imaging scans and breathing tests to track changes over time.
Boston, MassachusettsAges 18–80 - NCT07567235RecruitingPhase 1
CFH Protein Ice Microneedles for Radiation Skin Damage
This study tests a new treatment using ice microneedles to deliver a healing protein (CFH) to prevent skin scarring and fibrosis after radiation therapy for head and neck cancer. The goal is to reduce long-term skin damage from cancer treatment.
Chengdu, SichuanAges 18–75 - NCT07516951RecruitingPhase 2
Study of zampilimab for idiopathic pulmonary fibrosis
This trial tests an investigational drug called zampilimab for people with idiopathic pulmonary fibrosis (IPF). It aims to find a safe and effective dose that may slow lung function decline.
Hannibal, MissouriAges 40 years+ - NCT07508904Recruiting
Exercise effects in children with cystic fibrosis
This study tests whether a specific exercise program can improve muscle strength, breathing, and fitness in children with cystic fibrosis who are stable and able to exercise.
LahoreAges 6–18 - NCT07486206Recruiting
Optimizing follow-up for interstitial lung disease
This trial tests a new way to organize follow-up visits for people with interstitial lung disease (a group of lung conditions). It aims to make care simpler and more effective for patients who are already on treatment.
Granollers, BarcelonaAges 18 years+ - NCT07485543RecruitingEarly Phase 1
Inhaled genetic therapy for cystic fibrosis patients
This trial tests an inhaled medicine that delivers a corrective genetic message (mRNA) to lung cells in people with cystic fibrosis. It aims to see if the treatment is safe and can improve lung function over time.
Beijing, Beijing MunicipalityAges 12 years+ - NCT07464912RecruitingPhase 3
Testing TDI01 for idiopathic pulmonary fibrosis
This trial tests a new drug called TDI01 to see if it helps people with idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring. You may qualify if you have a confirmed IPF diagnosis and your lung function is stable enough.
Beijing, Beijing MunicipalityAges 40–80
Hear when a new Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for fibrosis?
- Yes. Clin2 currently lists 414 recruiting fibrosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a fibrosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a fibrosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.